Get the Stockscreener App
1.10
0.00%
0.00
Pre-market:
1.14
0.04
+3.64%
Invivyd Inc stock is traded at $1.10, with a volume of 2.21M.
It is up +0.00% in the last 24 hours and down -24.66% over the past month.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
See More
Previous Close:
$1.10
Open:
$1.12
24h Volume:
2.21M
Relative Volume:
0.78
Market Cap:
$324.07M
Revenue:
$53.43M
Net Income/Loss:
$-52.49M
P/E Ratio:
-3.0649
EPS:
-0.3589
Net Cash Flow:
$-58.29M
1W Performance:
+5.77%
1M Performance:
-24.66%
6M Performance:
-52.79%
1Y Performance:
+46.96%
1-Day Range:
$1.095
$1.15
1-Week Range:
$1.02
$1.18
52-Week Range:
$0.483
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.10 | 324.07M | 53.43M | -52.49M | -58.29M | -0.3589 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
Invivyd Q1 2026 earnings preview - MSN
IVVD News | INVIVYD INC (NASDAQ:IVVD) - ChartMill
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 - 富途牛牛
Invivyd (IVVD) director Ajay Royan receives stock options for 50,000 shares - Stock Titan
Invivyd (IVVD) director receives grant of 50,000 stock options at $1.04 - Stock Titan
Invivyd (IVVD) director Terrance McGuire granted 50,000 stock options at $1.04 - Stock Titan
Invivyd (IVVD) director receives 50,000 options at $1.04 strike price - Stock Titan
Invivyd grants options to director Paul Bolno | IVVD Insider Trading - Stock Titan
Invivyd (IVVD) director Tamsin Berry receives stock options for 50,000 shares - Stock Titan
IVVD stock tanks 19% today – but this analyst believes it has a potential upside of over 730% - MSN
H.C. Wainwright reiterates Invivyd stock rating on trial progress - Investing.com India
Invivyd Shareholders Reelect Board, Ratify PwC Auditor - TipRanks
Invivyd (IVVD) shareholders elect board and ratify PwC at 2026 meeting - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Invivyd(IVVD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
IVVD: Directors were elected and the auditor ratified, with no additional proposals or questions - TradingView
H.C. Wainwright reiterates Invivyd stock rating on trial progress By Investing.com - Investing.com South Africa
Invivyd Inc stock (US46186M1080): focus shifts to monoclonal antibody NVD200 as company updates pipe - AD HOC NEWS
Invivyd, Inc. (IVVD) reports Q1 loss, lags revenue estimates - MSN
Invivyd Q1 earnings call highlights - MSN
IVVD Reiterated by BTIG -- Price Target Maintained at $10.00 - GuruFocus
Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
Invivyd, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IVVD) 2026-05-17 - Seeking Alpha
Invivyd stock (US46186M1080): antibody specialist under pressure after Q1 miss and high short intere - AD HOC NEWS
Invivyd outlines VYD2311 path as PEMGARDA grows 22% year-over-year while DECLARATION recruitment nears completion - MSN
Invivyd (IVVD) Q1 2026 Earnings Transcript - AOL.com
Invivyd Earnings Call Highlights Trial Progress, Growth - The Globe and Mail
RA Capital-backed fund holds 21.34M IVVD warrant shares (IVVD) - Stock Titan
Point72 (IVVD) reports 43,931 shares; shared voting/dispositive power - Stock Titan
Invivyd, Inc. (NASDAQ:IVVD) Q1 2026 Earnings Call Transcript - Insider Monkey
Invivyd, Inc.Common Stock (NQ: IVVD - FinancialContent
Invivyd (NASDAQ:IVVD) Issues Earnings Results - MarketBeat
Invivyd Q1 2026 Earnings Call Transcript - MarketBeat
Invivyd, Inc. Q1 2026 10-Q Report: Financial Results, Revenue, and Net Loss Overview - Minichart
IVVD Stock Tanks 19% Today – But This Analyst Believes It Has A Potential Upside Of Over 730% - Stocktwits
Invivyd Reports Q1 2026 Financial Results: PEMGARDA Revenue Up 22%, Strong Pipeline Progress, and VYD2311 Pivotal Data Expected Q3 2026 18 - Minichart
Invivyd Q1 Earnings Call Highlights - Barchart.com
Earnings call transcript: Invivyd Q1 2026 sees earnings miss, stock dips By Investing.com - Investing.com Australia
IVVD: VYD2311 pivotal trial advances as PEMGARDA revenue grows 22% year-over-year, supporting expansion - TradingView
Earnings call transcript: Invivyd Q1 2026 sees earnings miss, stock dips - Investing.com
Invivyd Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Invivyd Releases Q1 2026 Financial Results - AlphaStreet
Invivyd (NASDAQ:IVVD) Q1 Miss Sends Shares Lower as PEMGARDA Revenue Falls Short and R&D Costs Surge - ChartMill
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Invivyd Posts Strong Q1 Results, Advances VYD2311 Programs - TipRanks
Invivyd : IVVD Q1 2026 Earnings Deck FINAL 2026513 - marketscreener.com
INVIVYD ($IVVD) Releases Q1 2026 Earnings - Quiver Quantitative
IVVD: Net loss increased to $41.4 million in Q1 2026, with cash reserves dropping to $184.2 million - TradingView
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allen Robert D. III | Chief Scientific Officer |
Feb 17 '26 |
Sale |
1.54 |
18,189 |
28,004 |
133,879 |
| Green Julie | Chief Human Resources Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Green Julie | Chief Human Resources Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Duke William E. | Chief Financial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Duke William E. | Chief Financial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
117,717 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
138,681 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 18 '26 |
Sale |
1.58 |
34,939 |
55,127 |
181,736 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 17 '26 |
Sale |
1.54 |
32,771 |
50,454 |
216,675 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):